Multiple sclerosis is often diagnosed in patients who are planning on having children.
Although multiple sclerosis does not negatively influence most pregnancy outcomes, less is …

Monoclonal antibodies have become a mainstay in the treatment of patients with relapsing
multiple sclerosis (RMS) and provide some benefit to patients with primary progressive MS …

Importance The magnitude of risk of pregnancy-related multiple sclerosis relapses,
particularly severe relapses, following natalizumab cessation is unclear, as is whether this …

Background Natalizumab is a humanized monoclonal antibody used for treatment of highly
active relapsing-remitting multiple sclerosis (MS). With more than 15 years of post-marketing …

Neurologists increasingly use anti-CD20 therapies, including for women of childbearing
age, despite these medications being unlicensed for use in pregnancy. Current evidence …

PURPOSE OF REVIEW Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders
(NMOSDs) are chronic autoimmune demyelinating conditions of the central nervous system …

Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, and degenerative
disease that is up to three times more frequent in young women. MS does not alter fertility …

Objective To determine the transfer of the monoclonal antibody natalizumab into breastmilk
and to evaluate drug and serum neurofilament light chain ((s) NfL) levels in natalizumab …

Multiple sclerosis (MS) is an autoimmune-mediated degenerative disease of the central
nervous system, characterized by inflammatory demyelination. It is primarily found in women …

Background and Objective Discontinuation of fingolimod≥ 2 months before pregnancy is
recommended to minimize potential teratogenicity. The magnitude of MS pregnancy relapse …